2-Phenylthiazole-4-Carboxylicacid Ethyl Ester

During the scale-up of a cGMP campaign for a Type‑II kinase inhibitor registered under a US DMF, the ethyl ester of 2-phenylthiazole-4-carboxylic acid was employed as a protected electrophile in a carbodiimide-mediated amide bond formation. The production sequence was executed in a 500 L glass-lined reactor fitted with a retreat-blade impeller and a baffle set, operated under nitrogen inertisation to maintain residual oxygen below 0.5 vol%. The compliance framework required full adherence to ICH Q7 Part II and 21 CFR 210/211, with specific attention to solvent residues controlled per USP 〈467〉 Procedure A. The process solvent, 2-methyltetrahydrofuran, was recovered by distillation and held to a Class 2 limit of ≤500 ppm in the isolated intermediate; benzene as a potential trace contaminant was monitored at ≤2 ppm per tight-specification ICH Q3C Option 1. The molar incorporation of the ethyl ester was set at 1.05 equivalents relative to the primary amine substrate – a deliberate excess established through DoE studies to offset the slow hydrolysis of the active ester generated in situ, while minimising the formation of a bis-acylated impurity that co-elutes at RRT 1.37. In a typical batch, 117 kg of the amine hydrochloride was suspended in a mixture of water and 2-MeTHF and neutralised with aqueous potassium carbonate to a biphasic endpoint of pH 8.3±0.2. The organic phase was dried by azeotropic distillation to a Karl Fischer endpoint of <0.05% water, then cooled to 0–5 °C. Simultaneously, a slurry of the 2-phenylthiazole-4-carboxylic acid ethyl ester, EDC·HCl (1.15 eq.), and HOBt·H₂O (1.10 eq.) in 2-MeTHF was stirred at 0 °C for 45 min to generate the HOBt active ester; the slurry was transferred via a vacuum-assisted closed transfer line into the amine solution, maintaining the internal jacket temperature at 2±2 °C for the first hour to suppress racemisation of the chiral centre adjacent to the nascent amide bond. After complete addition, the batch was warmed to 20 °C over 2 h and stirred for an additional 14 h, with conversion tracked by inline ReactIR monitoring the azide stretch of the remaining carbodiimide at 2118 cm⁻¹. Quenching was performed with 10% w/w aqueous citric acid to remove urea by-products, followed by a sodium bicarbonate wash to pH 7.2 and a water wash to conductivity ≤10 µS/cm. The organic layer was concentrated under reduced pressure at a jacket temperature not exceeding 45 °C to a target volume of 3 volumes relative to theoretical yield, then seeded with 0.5% w/w micronised seed crystals of the target intermediate. n-Heptane was added linearly over 3 h with a controlled cooling ramp to −5 °C; the resultant white crystalline solid was isolated on a 0.5 m² Hastelloy centrifuge, displacement-washed with chilled heptane, and dried in a double-cone tumble dryer at 35 °C and 50 mbar until the residual 2-MeTHF fell below the 5000-ppm ICH limit. The typical isolated yield was 86–89% of theory, with HPLC purity ≥99.5% by area at 254 nm. The terminal product of this sequence was a crystalline amide hydrochloride, the immediate precursor to the final API after BOC deprotection and final salt formation, registered for the treatment of a genetically defined non-small-cell lung cancer subpopulation.

Hydrolysis Without Epimerisation: A Kinetic Trap in Fungicide Intermediate Synthesis

In the manufacturing pathway of a second-generation succinate dehydrogenase inhibitor (SDHI) fungicide that targets the mitochondrial complex II of Zymoseptoria tritici, the ethyl ester serves as a transportable pro-acid – the free carboxylic acid being poorly soluble in common extraction solvents – and its release is timed to occur only after the resolution of a chiral amine intermediate. The process is conducted under the scope of an OECD 506-compliant five-batch analysis programme for active substance registration, with specifications aligned to FAO Specification 59 for technical-grade fungicides and a full REACH dossier for both the intermediate and the derived acid. The hydrolysis step is the critical control point: the ethyl ester is dissolved in a THF/water mixture (4:1 v/v) at a concentration of 1.0 M and treated with aqueous sodium hydroxide (30% w/w) at a substoichiometric initial charge of 0.95 equivalents; the remainder is fed by a pH-stat controller keeping the reaction mixture at pH 11.8±0.3 and a bulk temperature below 10 °C. Above 15 °C or above pH 13.2, decarboxylation accelerates to a rate of ≥2% per hour, causing an irreversible yield loss that is compounded by the formation of 2-phenylthiazole as a neutral impurity that partitions unfavourably into the final crystallised product. After complete saponification, the pH is adjusted to 2.5 with 6 N hydrochloric acid, causing the free acid to precipitate as a filterable solid that is washed with deionised water to a dried chloride content of <500 ppm. The downstream amide coupling with a substituted aniline possessing a cyclopropyl substituent required for target-site binding uses phosphorus oxychloride as the dehydrating agent in refluxing toluene at a mole ratio of acid:aniline:POCl₃ = 1.0:1.03:0.35. Unreacted aniline is scavenged with a 5% HCl scrub, and the technical-grade amide is crystallised from a toluene/n-heptane mixture to yield a product with a melting point of 148–150 °C and a purity of ≥96%. The final formulated product is a suspension concentrate (SC 250 g/L).

What Determines the Shelf-Life of an Alkoxycarbonyl Prodrug Intermediate?

When the ethyl ester is utilised as a handle to install a lipophilic alkoxycarbonyloxymethyl promoiety onto a phosphate or phosphonate drug candidate, the intrinsic moisture sensitivity of the sodium or potassium carboxylate salt obliges a sequence design that avoids isolation of the free acid. The synthesis is performed in accordance with ICH M7 additive for mutagenic impurity control, with a specific purge factor calculation for ethyl iodide, a potential by-product of the nucleophilic substitution, demonstrating a carryover of <0.15 ppm when the crystallisation solvent system uses ethyl acetate/n-heptane in a 3:7 ratio. The reaction is conducted in anhydrous N,N-dimethylformamide (water content <100 ppm by KF) containing a suspension of anhydrous potassium carbonate ( 325 mesh, 2.5 equivalents) and 0.95 equivalents of 2-phenylthiazole-4-carboxylic acid ethyl ester. Once the substrate sodium salt is completely dissolved at 45 °C, chloromethyl ethyl carbonate (1.20 equivalents) is metered over 60 min using a syringe pump to control the exotherm within ±3 °C of the setpoint. Off-line HPLC sampling at 15-min intervals tracks the formation of the protected intermediate and detects the under-alkylated parent acid; the addition is terminated when the parent acid area drops below 0.3%. The reaction mixture is diluted with MTBE and washed with 10% w/w sodium bicarbonate and water, then concentrated under reduced pressure. The residual DMF is azeotropically removed with toluene, and the crude oil is crystallised by addition of n-heptane at 50 °C followed by slow cooling to −10 °C. The isolated hydrate of the alkoxycarbonyl ester is stored under a positive nitrogen atmosphere at 2–8 °C, as accelerated stability studies at 40 °C/75% RH over 4 weeks have shown a 3.5% increase in the free acid impurity under caps with a desiccant only, making secondary packaging with aluminium foil heat-sealing mandatory. The terminal product is a chemically stable prodrug ready for final salt formation, intended for oral administration in a hepatitis D combination therapy.

In the context of low-bandgap donor–acceptor copolymers for non-fullerene organic photovoltaics (OPV), the electron-deficient thiazole ring has been incorporated into the polymer backbone via Stille polycondensation using the 2-phenylthiazole-4-carboxylate ethyl ester as a solubilising precursor. The material requirements for OPV-grade intermediates derive not from pharmacopoeias but from the specifications of IEC 61215-1-1 (materials qualification for photovoltaic modules) and the substance restrictions of RoHS 2011/65/EU, particularly the limitation of total halogens to <900 ppm post-polymerisation. The ethyl ester is first converted to a 2,5-dibrominated thiazole monomer through directed ortho-metallation and quenching with 1,2-dibromo-1,1,2,2-tetrachloroethane; the stoichiometric precision at this stage dictates the statistical distribution of monomer sequences in the final polymer. For the Stille coupling, the dibromide monomer is charged at 1.000 equivalents against 1.005 equivalents of a distannylated benzodithiophene comonomer to ensure bromine end-group deficiency, using Pd₂(dba)₃ (2 mol%) and P(o-tol)₃ (8 mol%) in rigorously degassed chlorobenzene at 0.15 M monomer concentration. The polymerisation is conducted in a sealed microwave reactor at 140 °C for 12 min, followed by an end-capping sequence with 2-(tributylstannyl)thiophene and 2-bromothiophene to remove residual metal-reactive termini. The resulting crude polymer is precipitated into acidified methanol and purified by sequential Soxhlet extraction with methanol, acetone, and hexane to strip oligomeric and palladium residues below 15 ppm (quantified by ICP-MS). The active fraction is collected in chloroform and re-precipitated; it exhibits a number-average molecular weight (Mn) of 38–42 kDa and a dispersity of 1.8–2.2 as determined by high-temperature GPC in 1,2,4-trichlorobenzene at 150 °C. The finished product is a dark-blue powder that serves as the donor polymer in a bulk-heterojunction ink formulated with a non-fullerene acceptor, screen-printed onto flexible barrier films for building-integrated photovoltaics.

Nucleophilic Substitution at the 4-Position for Asymmetric Thiazole Orange Analogues

To synthesise asymmetric cyanine dyes in which a 2-phenylthiazole moiety modulates the excited-state lifetime for DNA intercalation and fluorescence lifetime imaging (FLIM), the ethyl ester acts as an activated electrophile in a Knoevenagel-type condensation. Even though these materials are research-grade chemicals, suppliers of fluorescent probes often self-certify compliance with ISO 13485 for components used in in vitro diagnostic reagent kits, with trace-metal limits aligned to ICH Q3D Elemental Impurities guidance (oral permissible daily exposure extrapolated to reagent concentrations). The ester is condensed with a 1-methylbenzothiazolium salt carrying a quaternary nitrogen substituent, using a base system of triethylamine in anhydrous ethanol at a molar ratio of 1.00:1.05 (ester:azolium). The mixture is stirred under reflux (78 °C) for 6 h, then cooled to 0 °C to precipitate the crude dye. Recrystallisation is performed from ethanol/diethyl ether (1:3) to remove the unreacted positively charged precursor; residual solvent is removed in a vacuum oven at 40 °C and 10 mbar until the ethanol content is below 5000 ppm by headspace GC. The spectral properties of the dye – a fluorescence quantum yield of 0.15 in phosphate-buffered saline and an absorption maximum at 509 nm – are verified by UV-Vis and steady-state fluorimetry. The terminal product is a lyophilised dye packaged under argon and used for fluorescence in situ hybridisation (FISH) probe labelling.

When the Ethyl Ester is Retained into the Final Drug Substance as a Metabolic Soft Spot Modulator

In a medicinal chemistry programme targeting a class of macrocyclic peptidomimetics, the intact ethyl ester was deliberately carried through to the final API to attenuate cytochrome P450 3A4-mediated oxidation and to tune the logD at pH 7.4 to a narrow window of 2.0–2.5, as mandated by a PBPK-guided candidate selection criterion. The regulatory starting material strategy filed with the US FDA classified the intermediate containing the thiazole ester as an ICH Q11 starting material, with specifications governed by an internal monograph aligned to ICH Q6A decision tree #3. The acceptance criteria included individual unspecified impurities at ≤0.10%, enantiomeric excess of ≥99.0% by chiral HPLC, and palladium content from a prior Suzuki coupling measured by ICP-OES at ≤5 ppm. The critical amide bond formation used HATU as the coupling agent in DMF, with the azetidine hydrochloride salt being pre-neutralised with N,N-diisopropylethylamine (2.50 eq.) and the ethyl ester added at exactly 1.00 equivalent to avoid forming mixtures of diastereomeric amides. Process robustness trials highlighted that a water content above 0.2% in DMF caused a significant drop in conversion (from 95% to 72%) due to competing hydrolysis of the activated ester; therefore, pre-drying of lithium chloride salts used for solubility enhancement was mandatory. After isopropyl acetate extraction and a 5% LiCl wash, the solution was filtered through a 0.45 µm PTFE cartridge to remove particulate matter before a controlled antisolvent crystallisation with heptane/MTBE. The isolated final drug substance was milled with a 0.5 mm conical sieve and dried under full vacuum at 30 °C to furnish a white crystalline polymorph with a melting onset of 191–193 °C, matching the thermodynamically stable Form A. This compound entered Phase I clinical trials as a once-daily oral candidate for resistant hypertension.

In the pilot-scale synthesis of a fused heterocycle ligand for iridium(III)-based phosphorescent emitters used in solution-processed organic light-emitting diodes (OLEDs), the ethyl ester was exploited for its capacity to undergo Pd-catalysed direct C–H arylation at the 5-position. The absence of pharmacopoeial compendia for OLED intermediates obligates adherence to a supplier short-form specification that incorporates RoHS substance restrictions and a maximum outgassing criterion (weight loss ≤0.5% after 1 h at 200 °C, per TGA under nitrogen). The ester was reacted with a 2-arylpyridine bromo derivative under a catalytic system of Pd(OAc)₂ (5 mol%), P(t-Bu)₃·HBF₄ (10 mol%), and Cs₂CO₃ (2.0 eq.) in p-xylene at 130 °C for 30 h. After aqueous quenching and column chromatography on silica gel (gradient heptane→10% EtOAc), the product was sublimed at 190 °C and 10⁻⁶ mbar to achieve a sublimation yield of 74% and a purity of 99.9% by HPLC. The sublimed ligand was subsequently mixed with an iridium trichloride hydrate precursor in a 2.2:1 molar ratio and reacted in ethoxyethanol at 120 °C to produce the heteroleptic emitter. The final doped film in a mCBP host at 8 wt% emitter concentration gave a photoluminescence quantum yield of 0.78 and a CIE 1931 coordinate of (0.34, 0.61), characterising it as a green emitter for display applications. Published data for the specific device lifetime at 1000 cd/m² in this exact configuration is limited, but extrapolation from accelerated aging at 70 °C projects an LT80 exceeding 280 h, sufficient for early-stage prototype evaluation.